|
Altar CA, Boylan CB, Jackson C, Hershenson S, Miller J, Wiegand SJ, Lindsay RM and Hyman C (1992) Brain-derived neurotrophic factor augments rotational behavior and nigrostriatal dopamine turnover in vivo. Proc Natl Acad Sci U S A 89(23):11347-11351.
Andrew R, Watson DG, Best SA, Midgley JM, Wenlong H and Petty RK (1993) The determination of hydroxydopamines and other trace amines in the urine of parkinsonian patients and normal controls. Neurochem Res 18(11):1175-1177.
Ashkenazi A and Dixit VM (1998) Death receptors: signaling and modulation. Science 281(5381):1305-1308.
Barger SW, Fiscus RR, Ruth P, Hofmann F and Mattson MP (1995) Role of cyclic GMP in the regulation of neuronal calcium and survival by secreted forms of beta-amyloid precursor. J Neurochem 64(5):2087-2096.
Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R and Verna JM (2001) Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson''s disease. Prog Neurobiol 65(2):135-172.
Bove J, Prou D, Perier C and Przedborski S (2005) Toxin-induced models of Parkinson''s disease. NeuroRx 2(3):484-494.
Bruchelt G, Schraufstatter IU, Niethammer D and Cochrane CG (1991) Ascorbic acid enhances the effects of 6-hydroxydopamine and H2O2 on iron-dependent DNA strand breaks and related processes in the neuroblastoma cell line SK-N-SH. Cancer Res 51(22):6066-6072.
Canals S, Casarejos MJ, de Bernardo S, Rodriguez-Martin E and Mena MA (2001) Glutathione depletion switches nitric oxide neurotrophic effects to cell death in midbrain cultures: implications for Parkinson''s disease. J Neurochem 79(6):1183-1195.
Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S and Reed JC (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282(5392):1318-1321.
Chien WL, Liang KC, Teng CM, Kuo SC, Lee FY and Fu WM (2003) Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl) -1-benzyl-indazole. Mol Pharmacol 63(6):1322-1328.
Chien WL, Liang KC, Teng CM, Kuo SC, Lee FY and Fu WM (2005) Enhancement of learning behaviour by a potent nitric oxide-guanylate cyclase activator YC-1. Eur J Neurosci 21(6):1679-1688.
Choi WS, Canzoniero LM, Sensi SL, O''Malley KL, Gwag BJ, Sohn S, Kim JE, Oh TH, Lee EB and Oh YJ (1999) Characterization of MPP(+)-induced cell death in a dopaminergic neuronal cell line: role of macromolecule synthesis, cytosolic calcium, caspase, and Bcl-2-related proteins. Exp Neurol 159(1):274-282.
Chun YS, Yeo EJ, Choi E, Teng CM, Bae JM, Kim MS and Park JW (2001) Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells. Biochem Pharmacol 61(8):947-954.
Chun YS, Yeo EJ, and Park JW (2004) Versatile pharmacological actions of YC-1:anti-platelet to anticancer. Cancer Lett. 207(1):1-7.
Cohen G and Heikkila RE (1974) The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J Biol Chem 249(8):2447-2452.
Curtius HC, Wolfensberger M, Steinmann B, Redweik U and Siegfried J (1974) Mass fragmentography of dopamine and 6-hydroxydopamine. Application to the determination of dopamine in human brain biopsies from the caudate nucleus. J Chromatogr 99(0):529-540.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y and Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91(2):231-241.
Dauer W and Przedborski S (2003) Parkinson''s disease: mechanisms and models. Neuron 39(6):889-909.
Davis GC, Williams AC, Markey SP, Ebert MH, Caine ED, Reichert CM and Kopin IJ (1979) Chronic Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1(3):249-254.
Desole MS, Esposito G, Fresu L, Migheli R, Enrico P, Miele M, De Natale G and Miele E (1993) Correlation between 1-methyl-4-phenylpyridinium ion (MPP+) levels, ascorbic acid oxidation and glutathione levels in the striatal synaptosomes of the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated rat. Neurosci Lett 161(2):121-123.
Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P and Marsden CD (1989) Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson''s disease. J Neurochem 52(6):1830-1836.
Fadeel B, Orrenius S and Zhivotovsky B (1999) Apoptosis in human disease: a new skin for the old ceremony? Biochem Biophys Res Commun 266(3):699-717.
Fahn S and Cohen G (1992) The oxidant stress hypothesis in Parkinson''s disease: evidence supporting it. Ann Neurol 32(6):804-812.
Farinelli SE, Park DS and Greene LA (1996) Nitric oxide delays the death of trophic factor-deprived PC12 cells and sympathetic neurons by a cGMP-mediated mechanism. J Neurosci 16(7):2325-2334.
Fiscus RR (2002) Involvement of cyclic GMP and protein kinase G in the regulation of apoptosis and survival in neural cells. Neurosignals 11(4):175-190.
Fiscus RR, Tu AW and Chew SB (2001) Natriuretic peptides inhibit apoptosis and prolong the survival of serum-deprived PC12 cells. Neuroreport 12(2):185-189.
Friebe A and Koesling D (1998) Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 53(1):123-127.
Friebe A and Koesling D (2003) Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93(2):96-105.
Garthwaite G, Goodwin DA, Neale S, Riddall D and Garthwaite J (2002) Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition. Mol Pharmacol 61(1):97-104.
Glinka YY and Youdim MB (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J Pharmacol 292(3-4):329-332.
Golbe LI (1991) Young-onset Parkinson''s disease: a clinical review. Neurology 41(2 ( Pt 1)):168-173.
Hail N, Jr., Carter BZ, Konopleva M and Andreeff M (2006) Apoptosis effector mechanisms: A requiem performed in different keys. Apoptosis in press.
Hengartner MO (2000) The biochemistry of apoptosis. Nature 407(6805):770-776.
Hughes AJ, Daniel SE, Blankson S and Lees AJ (1993) A clinicopathologic study of 100 cases of Parkinson''s disease. Arch Neurol 50(2):140-148.
Hwang TL, Hung HW, Kao SH, Teng CM, Wu CC and Cheng SJ (2003) Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway. Mol Pharmacol 64(6):1419-1427.
Javitch JA and Snyder SH (1984) Uptake of MPP(+) by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol 106(2):455-456.
Jin K, Mao XO, Zhu Y and Greenberg DA (2002) MEK and ERK protect hypoxic cortical neurons via phosphorylation of Bad. J Neurochem 80(1):119-125.
Johnson DE (2000) Noncaspase proteases in apoptosis. Leukemia 14(9):1695-1703.
Ko FN, Wu CC, Kuo SC, Lee FY and Teng CM (1994) YC-1, a novel activator of platelet guanylate cyclase. Blood 84(12):4226-4233.
Kroemer G and Reed JC (2000) Mitochondrial control of cell death. Nat Med 6(5):513-519.
Kumar R, Agarwal AK and Seth PK (1995) Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem 64 (4) : 1703-1707.
Langston JW, Ballard P, Tetrud JW and Irwin I (1983) Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219(4587):979-980.
Lee HJ, Bach JH, Chae HS, Lee SH, Joo WS, Choi SH, Kim KY, Lee WB and Kim SS (2004) Mitogen-activated protein kinase/extracellular signal-regulated kinase attenuates 3-hydroxykynurenine-induced neuronal cell death. J Neurochem 88(3):647-656.
Li Y, Maher P and Schubert D (1997) Requirement for cGMP in nerve cell death caused by glutathione depletion. J Cell Biol 139(5):1317-1324.
Liu L, Li H, Underwood T, Lloyd M, David M, Sperl G, Pamukcu R and Thompson WJ (2001) Cyclic GMP-dependent protein kinase activation and induction by exisulind and CP461 in colon tumor cells. J Pharmacol Exp Ther 299(2):583-592.
Loweth AC, Williams GT, Scarpello JH and Morgan NG (1997) Evidence for the involvement of cGMP and protein kinase G in nitric oxide-induced apoptosis in the pancreatic B-cell line, HIT-T15. FEBS Lett 400(3):285-288.
Luthman J, Fredriksson A, Sundstrom E, Jonsson G and Archer T (1989) Selective lesion of central dopamine or noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage. Behav Brain Res 33(3):267-277.
Majno G and Joris I (1995) Apoptosis, oncosis, and necrosis. An overview of cell death. Am J Pathol 146(1):3-15.
Mizuno Y, Suzuki K, Sone N and Saitoh T (1987) Inhibition of ATP synthesis by 1-methyl-4-phenylpyridinium ion (MPP+) in isolated mitochondria from mouse brains. Neurosci Lett 81(1-2):204-208.
Montoliu C, Llansola M, Kosenko E, Corbalan R and Felipo V (1999) Role of cyclic GMP in glutamate neurotoxicity in primary cultures of cerebellar neurons. Neuropharmacology 38(12):1883-1891.
Nicklas WJ, Vyas I and Heikkila RE (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1 -methyl-4-pheny l-1,2,5,6 - tetrahydropyridine. Life Sci 36(26):2503-2508.
Nicotra A and Parvez SH (2000) Cell death induced by MPTP, a substrate for monoamine oxidase B. Toxicology 153(1-3):157-166.
Ochu EE, Rothwell NJ and Waters CM (1998) Caspases mediate 6-hydroxydopamine-induced apoptosis but not necrosis in PC12 cells. J Neurochem 70(6):2637-2640.
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR, Pfeffer LM and Donner DB (1999) NF-kappaB activation by tumour necrosis factor requires the Akt serine-threonine kinase. Nature 401(6748):82-85.
Pollman MJ, Yamada T, Horiuchi M and Gibbons GH (1996) Vasoactive substances regulate vascular smooth muscle cell apoptosis. Countervailing influences of nitric oxide and angiotensin II. Circ Res 79(4):748-756.
Porter CC, Totaro JA and Stone CA (1963) Effect of 6-hydroxydopamine and some other compounds on the concentration of norepinephrine in the hearts of mice. J Pharmacol Exp Ther 140:308-316.
Przedborski S and Ischiropoulos H (2005) Reactive oxygen and nitrogen species: weapons of neuronal destruction in models of Parkinson''s disease. Antioxid Redox Signal 7(5-6):685-693.
Przedborski S, Jackson-Lewis V, Yokoyama R, Shibata T, Dawson VL and Dawson TM (1996) Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc Natl Acad Sci U S A 93(10):4565-4571.
Reed JC, Jurgensmeier JM and Matsuyama S (1998) Bcl-2 family proteins and mitochondria. Biochim Biophys Acta 1366(1-2):127-137.
Saner A and Thoenen H (1971) Model experiments on the molecular mechanism of action of 6-hydroxydopamine. Mol Pharmacol 7(2):147-154.
Schober A (2004) Classic toxin-induced animal models of Parkinson''s disease: 6-OHDA and MPTP. Cell Tissue Res 318(1):215-224.
Senoh S, Witkop B (1959) Non-enzymatic conversions of dopamine to norepinephrine and trihydroxyphenetylamines. J Am Chem Soc 81:6222–6231
Senoh S, Creveling CR, Udenfriend S, Witkop B (1959) Chemical, enzymatic, and metabolic studies on the mechanism of oxidation of dopamine. J Am Chem Soc 81:6236–6240
Seyfried J, Soldner F, Kunz WS, Schulz JB, Klockgether T, Kovar KA and Wullner U (2000) Effect of 1-methyl-4-phenylpyridinium on glutathione in rat pheochromocytoma PC 12 cells. Neurochem Int 36(6):489-497.
Sofic E, Lange KW, Jellinger K and Riederer P (1992) Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson''s disease. Neurosci Lett 142(2):128-130.
Soldner F, Weller M, Haid S, Beinroth S, Miller SW, Wullner U, Davis RE, Dichgans J, Klockgether T and Schulz JB (1999) MPP+ inhibits proliferation of PC12 cells by a p21(WAF1/Cip1)-dependent pathway and induces cell death in cells lacking p21(WAF1/Cip1). Exp Cell Res 250(1):75-85.
Spina MB, Squinto SP, Miller J, Lindsay RM and Hyman C (1992) Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system. J Neurochem 59(1):99-106.
Suenobu N, Shichiri M, Iwashina M, Marumo F and Hirata Y (1999) Natriuretic peptides and nitric oxide induce endothelial apoptosis via a cGMP-dependent mechanism. Arterioscler Thromb Vasc Biol 19(1):140-146.
Teng CM, Wu CC, Ko FN, Lee FY and Kuo SC (1997) YC-1, a nitric oxide-independent activator of soluble guanylate cyclase, inhibits platelet-rich thrombosis in mice. Eur J Pharmacol 320(2-3):161-166.
Tsujimoto Y (2003) Cell death regulation by the Bcl-2 protein family in the mitochondria. J Cell Physiol 195(2):158-167.
von Coelln R, Kugler S, Bahr M, Weller M, Dichgans J and Schulz JB (2001) Rescue from death but not from functional impairment: caspase inhibition protects dopaminergic cells against 6-hydroxydopamine-induced apoptosis but not against the loss of their terminals. J Neurochem 77(1):263-273.
Wang JP, Chang LC, Huang LJ and Kuo SC (2001) Inhibition of extracellular Ca(2+) entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils. Biochem Pharmacol 62(6):679-684.
Wegener JW and Nawrath H (1997) Differential effects of isoliquiritigenin and YC-1 in rat aortic smooth muscle. Eur J Pharmacol 323(1):89-91.
Woodgate A, MacGibbon G, Walton M and Dragunow M (1999) The toxicity of 6-hydroxydopamine on PC12 and P19 cells. Brain Res Mol Brain Res 69(1):84-92.
Wu CF, Bishopric NH and Pratt RE (1997) Atrial natriuretic peptide induces apoptosis in neonatal rat cardiac myocytes. J Biol Chem 272(23):14860-14866.
Wyllie AH, Kerr JF and Currie AR (1980) Cell death: the significance of apoptosis. Int Rev Cytol 68:251-306.
Yasuhara S, Zhu Y, Matsui T, Tipirneni N, Yasuhara Y, Kaneki M, Rosenzweig A and Martyn JA (2003) Comparison of comet assay, electron microscopy, and flow cytometry for detection of apoptosis. J Histochem Cytochem 51(7):873-885.
Zoratti M and Szabo I (1995) The mitochondrial permeability transition. Biochim Biophys Acta 1241(2):139-176.
|